Slide 1: Corporate Presentation December 2016
Corporate Presentation December 2016
Slide 2: Safe Harbor Statement
Safe Harborstatement Forward-Looking StatementsThis presentation contains certain statements that may be deemed to be “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended.Forward looking statements app
Slide 3: Our Mission
OurMission 3 Provide A New Vision for Colorectal Cancer Prevention That improves the patient experience and maximizes the number screened
Slide 4: About Check-Cap
About Check-Cap 4 Technology Ingestible X-ray scanning capsule Tracking control and data collection unitImage processing and viewing Clinical Trials $56mn raised Nasdaq: CHEK Ongoing in IsraelPlan to initiate U.S. pivotal trial in 2018 GE, Fosun Pharma,Pontifax Founded – 2005, Employees – 47 Located
Slide 5: Colorectal Cancer a major public health problem
Colorectal Cancer a major public health problem 5 137k50k Source: American Cancer Society World Health Organization J Natl Cancer Inst. 2011; 103:1-12 (Mariotto) 134k49k 471k228k 253k139k 113k48k 1.36m694k Annual new cases world-wide -Annual deaths world-wide - Second leading cause of cancer deaths
Slide 6: Colorectal Cancer highly preventable
Colorectal Cancer highly preventable 6 Source: Gastro 1997;112:594-692 (Winawer) WEO Atlas, NCI Small Adenomatous Polyp (< 1cm) Colorectal Cancer Pre-cancerous phase, readily detectable by structural examinations of the colon Asymptomatic patient Cancer patient ~10 years
Slide 7: CRC screening tests: cancer prevention and cancer detection
Source: AGA Institute Guidelines for the Early Detection of Colorectal Cancer and Adenomatous Polyps Gastroenterology 2008; 134: 1570-1595 (Levin) CA Cancer J Clin 2014;64:104-17 (Seigel) CRC screening testscancer prevention and cancer detection 7 Significant declines in colorectal cancer incidence
Slide 8: Screening in the U.S. a substantially underused strategy
Screening in the U.S.a substantially underused strategy 8 Sources: CDC NHIS Survey results MMWR 2015 USPSTF, JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989 2000 2010 2013 2018 80% 59% 35% goal Screening rates USPSTF recommendation recognizes that different screening tests may lessattractiv
Slide 9: Removal of prep may increase screening rates
Removal of prepmay increase screening rates 9 15% 32% 21% 13% 11% 8% 86% of respondents would be much or somewhat more likely to undergo screening if laxative prep were to be removed. Source: Mayo Clinic Proc. 2007;82(6):666-671 (Beebe)
Slide 10: Check-Cap System
Check-CapSystem Ingestible scanning capsule 1 Capsule Positioning System - Biocompatible patch worn on patient's back for tracking capsule and recording data 2 3D colon imageviewer 3 Imaging Data + Positioning Data Data upload The Check-Cap System is not available for sale or clinical use in any jur
Slide 11: Ultra-low dose X-ray scanning capsule
Ultra-low dose X-ray scanning capsule 11 Patented technology detects photons XRF CMT from Compton Back-scattering and X-Ray Fluorescence As the capsule moves naturally, it scans the inner lining of the colon in a 360 degree arc, scanning only when in motion Patients drink a small amount of contrast
Slide 12: Patients continue their daily routine
Patientscontinue their daily routine 12 As the capsule travels naturally, it transmits scanning and location Data to the Capsule Positioning System, mapping the structures of the internal colon. The capsule is excreted naturally and the patient is notified. Capsule route in colon Capsule Positioning
Slide 13: Physician review of clinical images
Physician reviewof clinical images 13 Image taken during colonoscopy of a 20-30mm polyp Image for illustration only
Slide 14: Clinical data generation
Clinical datageneration 14 75 patients 2010 Capsule motility Germany/Israel Israel Israel/EU 1st clinical scanning capsule Source: Gut. 2016 Mar;65(3):371-3 (Gluck)
Slide 15: Case study: polyp in the sigmoid colon
15 Case studypolyp in the sigmoid colon Fillet-typeprocessing Tube-type processing Image taken during screening colonoscopy of a 20mm polyp on a large stem in the sigmoid colon A section of the sigmoid colon where a polyp was located A 3D map of the colon as captured by the system A/P view
Slide 16: Case study: polyp in the ascending colon
16 Case studypolyp in the ascending colon Fillet-typeprocessing Tube-type processing Image taken during colonoscopy of a 4mm sessile polyp on a haustra in the ascending colon A section of the ascending colon where a polyp was located A 3D map of the colon as captured by the system
Slide 17: Compelling market opportunity
Compelling market opportunity 17 $4B annual U. S. market opportunity** Source: * - population between ages 50-84 at average risk, U.S. Census Bureau, Pop. Division, 2014, company estimates ** - For patients screened once every 5 years at average Check-Cap System price of $600 J Clin Gastroenterol 20
Slide 18: Intellectual Property robust portfolio
Intellectual Property robust portfolio 18 Core patents granted in major jurisdictions 23 granted, 2 allowed, and 37 pending worldwide including the U.S. PTO, European Patent Organization, China, Japan, & India covering the core technology: Intra-Lumen Polyp Detection – system and method for an inges
Slide 19: Management
Management 19 Dr. Yoav KimchyFounder & CTO Alex Ovadia COO Dr. Walt Robb Steve Hanley Yuval Yanai Dr. Mary Jo Gorman XQ LinTomer Kariv Bill Densel Bill Densel CEO Lior Torem CFO BOD
Slide 20: Financial & Corporate summary
Financial & Corporate summary 20 $13.5 million cash as of September 30, 2016 Financial Position • US IPO: February 2015• Traded on the NASDAQ: CHEK• Warrants traded on the NASDAQ: CHEKW• 15.0 million ordinary shares outstanding• Affiliate ownership: 17.3% Capital Structure
Slide 21: Target milestones
Targetmilestones 21 * Capital and strategic partner dependent Design release and transfer to productionComplete multi-center clinical study Data release from multi-center clinical studyCE Mark submission U.S Pilot Trial initiation H216 H117 01/08 U.S. Pivotal Trial initiation EU Post Market Study in
Slide 22: Investment highlights
Investment highlights 22 Novel technology with significant market opportunityPatient-centric approach Proof of concept clinically demonstratedMacro environment alignment
Slide 23: A New Vision For Colorectal Cancer Prevention
A New Vision For Colorectal Cancer Prevention